⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
PRMT6 Inhibitors (EPZ020411)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-12 — PRMT6 drives hearing loss by promoting asymmetric arginine dimethylation-mediated FOXG1 degradation and suppressing mitophagy.: Mouse + HEI-OC1 study: PRMT6 asymmetrically dimethylates FOXG1, accelerating its degradation and suppressing mitophagy in D-gal-induced cochlear aging; PRMT6 silencing or EPZ020411 restores mitophagy and reverses senescence/ABR threshold elevation, defining a PRMT6–FOXG1–mitophagy axis in ARHL (no human data). [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
PRMT6 drives hearing loss by promoting asymmetric arginine dimethylation-mediated FOXG1 degradation and suppressing mitophagy.
12-aug-2026
novelty 3
per-area 3
strengthens